Press release
Cyclodextrin in Pharma Market to Surpass USD 650 Million by 2034
Cyclodextrin in Pharma Market
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/63090
Market Overview: Formulation's Molecular Enhancer
According to Exactitude Consultancy, the Global Cyclodextrin in Pharma Market was valued at USD 325 million in 2024 and is projected to reach USD 650 million by 2034, growing at a CAGR of 7.1% during the forecast period.
Key Highlights:
• 2024 Market Size: USD 325 Million
• 2034 Forecast: USD 650 Million
• CAGR (2024-2034): 7.1%
• Primary Drivers: Increasing use in poorly soluble drug formulations, favorable regulatory outlook, and rising biologics delivery innovations
• Major Challenges: High cost of modified cyclodextrins and limited availability in emerging markets
• Leading Players: Wacker Chemie AG, Roquette Frères, Ligand Pharmaceuticals, Cyclolab, Junsei Chemical, and Merck KGaA
Segmentation Analysis
By Type
• Alpha-Cyclodextrin
• Beta-Cyclodextrin
• Gamma-Cyclodextrin
• Modified Cyclodextrins (Hydroxypropyl, Sulfobutyl Ether, Methylated)
By Application
• Solubility Enhancement
• Stability Improvement
• Controlled Drug Release
• Taste Masking
• Biologic Delivery
• Ophthalmic and Nasal Drug Formulations
By Drug Form
• Oral Solids (Tablets, Capsules)
• Injectables
• Topicals & Creams
• Ophthalmics
• Intranasal Formulations
By End User
• Pharmaceutical Companies
• Biopharmaceutical Manufacturers
• Contract Manufacturing Organizations (CMOs)
• Academic & Research Institutes
Explore Full Report here: https://exactitudeconsultancy.com/reports/63090/global-cyclodextrin-in-pharma-market
Summary:
Beta- and gamma-cyclodextrins are most widely used due to their suitable cavity sizes and proven pharmaceutical safety. Modified cyclodextrins, particularly SBE-β-CD and HP-β-CD, are gaining market share for injectables and biologics. Applications span from solubility enhancement in BCS Class II/IV drugs to taste masking and nasal peptide delivery systems.
Regional Analysis
North America
• Largest market, supported by FDA-approved cyclodextrin-based drug formulations, advanced R&D, and strong presence of drug formulation players.
• The U.S. leads in injectable drugs and orphan drug programs that increasingly rely on modified cyclodextrins.
Europe
• Regulatory support from EMA for several cyclodextrin derivatives.
• Countries like Germany and France are leveraging cyclodextrins in controlled release and ophthalmic drugs.
• Increased academic research collaborations on novel drug delivery platforms.
Asia-Pacific
• Fastest-growing region, led by India, China, Japan, and South Korea.
• Growing local production of beta-cyclodextrin, combined with a surge in generic and specialty drug development.
• Rising government focus on pharmaceutical exports and formulation modernization.
Middle East & Africa
• Niche growth fueled by demand for stable injectable and pediatric drugs.
• Cyclodextrins gaining traction for temperature-sensitive drug stabilization in hot climates.
Latin America
• Brazil and Mexico show increasing interest in formulation upgrades, with pharma companies exploring solubility-enhancing excipients.
• Moderate adoption in orphan drug and specialty care segments.
Summary:
While North America and Europe lead in regulatory approvals and clinical deployment, Asia-Pacific is fast becoming a manufacturing and formulation hub. Regional trends are shaped by pharmaceutical infrastructure maturity, local API capabilities, and drug innovation initiatives.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=63090
Market Dynamics
Key Growth Drivers
• Poor Solubility Challenges in Drug Pipelines: Over 40% of new chemical entities (NCEs) face solubility issues-cyclodextrins offer a proven solution to improve oral and injectable bioavailability.
• Rise in Biologics and Peptides: Cyclodextrins are increasingly used in intranasal and injectable delivery systems for sensitive biomolecules.
• Regulatory Support for Modified Cyclodextrins: HP-β-CD and SBE-β-CD have gained GRAS and EMA approval for use in multiple drug formulations.
• Improved Drug Stability and Reduced Toxicity: Cyclodextrins help reduce API degradation, irritation, and dose-dependent side effects.
• Growing CMO/CDMO Adoption: Contract manufacturing organizations are adopting cyclodextrin-based platforms for complex formulation contracts.
Key Challenges
• Cost of High-Purity Modified Cyclodextrins: Especially in injectable-grade derivatives, pricing and supply chain complexity pose a challenge.
• Limited Awareness in Developing Markets: Small pharma players may lack technical understanding or resources to adopt advanced excipients.
• Formulation Compatibility Constraints: Cyclodextrins may interact with APIs or excipients, requiring careful screening during development.
Latest Trends
• Cyclodextrin-based Injectable Platforms: Widely used in anti-fungal, anticancer, and CNS drugs.
• Taste Masking in Pediatrics: Cyclodextrins help formulate palatable pediatric syrups and chewables, improving compliance.
• Gene and RNA Delivery Vehicles: Cyclodextrins are being researched as non-viral carriers for nucleic acid delivery.
• Green and Bio-based Cyclodextrin Production: Sustainable synthesis methods gaining ground due to clean label excipient demand.
Competitor Analysis
Key Market Players
• Wacker Chemie AG - Leading supplier of cyclodextrin derivatives for pharmaceutical, cosmetic, and food applications.
• Roquette Frères - Offers pharmaceutical-grade Kleptose® line of HPβCD and methylated cyclodextrins.
• Ligand Pharmaceuticals - Developed Captisol® (SBE-β-CD), used in FDA-approved drugs like AmBisome and Nexterone.
• Cyclolab Cyclodextrin Research & Development Ltd. - Specialist in custom cyclodextrin formulation and analytical services.
• Merck KGaA (MilliporeSigma) - Provides high-purity research-grade and GMP-certified cyclodextrins.
• Junsei Chemical Co. Ltd. - Supplies cyclodextrins across APAC laboratories and small pharma companies.
• Zhiyuan Biotechnology Co. Ltd. - Chinese producer of natural and modified β-CD and γ-CD for domestic and export markets.
• Tosoh Corporation - Focuses on specialty HPβCD for injectable systems.
• Ashland Global - Developing cyclodextrin-enabled polymeric drug delivery systems.
• Shandong Xinda Fine Chemical Co. Ltd. - Supplier of high-volume β-cyclodextrin and food-grade CD derivatives.
Summary:
The market is moderately consolidated with specialized suppliers, pharma ingredient giants, and contract developers. Players are competing based on product purity, GMP compliance, API compatibility, and global distribution capabilities. Strategic alliances with drug developers, CDMOs, and academic labs are crucial for pipeline adoption.
Conclusion: Cyclodextrins-The Silent Workhorse of Pharmaceutical Innovation
From enabling the delivery of insoluble drugs to stabilizing injectables and taste-masking pediatric formulations, cyclodextrins have become indispensable in modern pharmaceutical development. As the industry pivots toward personalized medicine, complex APIs, and patient-friendly formulations, the use of cyclodextrin-based excipients is set to rise.
Opportunities Ahead:
• Expansion of cyclodextrin-based nasal and ocular drug delivery
• Adoption in high-value biologic formulations and biosimilars
• Growth of GMP cyclodextrin supply chains in Asia
• Research into gene therapy and RNA drug carriers using CD inclusion complexes
By 2034, cyclodextrins will no longer be just solubility enhancers-they'll be key enablers of safe, stable, and effective drug formulations across global markets.
This report is also available in the following languages : Japanese (医薬品市場におけるシクロデキストリン), Korean (제약 시장의 사이클로덱스트린), Chinese (环糊精在医药市场), French (Cyclodextrine sur le marché pharmaceutique), German (Cyclodextrin im Pharmamarkt), and Italian (Ciclodestrina nel mercato farmaceutico), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/reports/63090/global-cyclodextrin-in-pharma-market#request-a-sample
Related Reports:
Phone Lens Market
https://exactitudeconsultancy.com/reports/61704/global-phone-lens-market
Quartz Crystal Oscillators Market
https://exactitudeconsultancy.com/reports/61708/global-quartz-crystal-oscillators-market
MPO Fiber Optic Patch Cord Market
https://exactitudeconsultancy.com/reports/61710/global-mpo-fiber-optic-patch-cord-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cyclodextrin in Pharma Market to Surpass USD 650 Million by 2034 here
News-ID: 4107838 • Views: …
More Releases from Exactitude Consultancy
Multiple Myeloma Market is expected to reach USD 46.3 billion by 2034
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells in the bone marrow. It is the second most common blood cancer after non-Hodgkin lymphoma and is associated with bone pain, anemia, renal dysfunction, and increased susceptibility to infections.
Over the next decade, the multiple myeloma market is expected to see substantial growth driven by immunotherapies, proteasome inhibitors, monoclonal antibodies, and CAR-T cell therapy. Advances in…
Metastatic Castration-Resistant Prostate Cancer Market is expected to reach USD …
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer where the disease progresses despite androgen deprivation therapy (ADT). It is one of the most challenging forms of prostate cancer to treat, often associated with poor survival rates and high symptom burden.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70869
Over the next decade, the mCRPC market is set to expand significantly due to the growing adoption of…
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2 …
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural lining of the lungs, most often caused by prolonged asbestos exposure. It is associated with a poor prognosis due to late-stage diagnosis and limited curative options. Traditionally treated with surgery, chemotherapy, and radiation, the MPM market is undergoing transformation as immunotherapy, targeted agents, and advanced imaging gain traction.
Download Full PDF Sample Copy of Market Report…
Low-Grade Glioma Market is expected to reach USD 2.75 billion by 2034
Low-grade gliomas (LGGs) are slow-growing primary brain tumors classified as WHO grade I or II, most commonly including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. Although generally associated with better prognosis compared to high-grade gliomas, LGGs can progress to higher grades over time, necessitating long-term management.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70865
The LGG market is set for significant growth over the next decade, driven by advances in molecular profiling,…
More Releases for Cyclodextrin
Cyclodextrin Market Size Opportunities and Challenges for the Future
The global cyclodextrin market is expected to reach approximately USD 15.1 billion by 2033, growing from USD 8.78 billion in 2024 at a compound annual growth rate (CAGR) of 6.2% during the forecast period from 2025 to 2033.
Cyclodextrin Market Overview
Cyclodextrin market growth is driven by increasing demand for efficient and cost-effective mineral exploration techniques, particularly in regions with challenging terrain. Air core drilling is favored for its lower environmental impact,…
Cyclodextrin Market to Expand Nearly Twofold by 2030
Cyclodextrin is highly soluble along with other properties, which makes it an ideal solution to use in pharmaceutical products. Pharmaceutical manufacturers are seeking the perfect pharmaceutical API and intermediate that can offer proper solubility and bio ability to drugs. The aqueous solubility of poorly water-soluble drugs has become a major concern in today's pharmaceutical industry.
Cyclodextrin has emerged as a beneficial solution for this problem. On the back of this…
Cyclodextrin Market to Expand Nearly Twofold by 2030
Cyclodextrin is highly soluble along with other properties, which makes it an ideal solution to use in pharmaceutical products. Pharmaceutical manufacturers are seeking the perfect pharmaceutical API and intermediate that can offer proper solubility and bio ability to drugs. The aqueous solubility of poorly water-soluble drugs has become a major concern in today's pharmaceutical industry. Cyclodextrin has emerged as a beneficial solution for this problem. On the back of this…
Cyclodextrin Market Reflect Impressive Growth Rate to During 2028
Cyclodextrin Market Outlook
Cyclodextrins are cyclic oligosaccharides that are produced by enzymatic conversion of starch. Cyclodextrins consists of a macrocyclic ring of glucose joined together by α-1, 4 glycosidic bonds. The production of cyclodextrin is reported from different starch sources such as tapioca, rice, and wheat, potato, and corn. Cyclodextrins are of three types alpha-cyclodextrin, beta-cyclodextrin, and gamma-cyclodextrin. Each type contains a different number of glucose subunits. Alpha-cyclodextrins contains 6…
Global Cyclodextrin Market Analysis by 2020-2025
Scope of the Report:
The global Cyclodextrin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.8%% in the forecast period of 2020 to 2025 and will expected to reach USD 251.7 million by 2025, from USD 200.6 million in 2019.
Market segmentation
Cyclodextrin market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate…
Cyclodextrin Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Cyclodextrin market analysis, which studies the Cyclodextrin's industry coverage, current market competitive status, and market outlook and forecast by 2025.
Global “Cyclodextrin Market 2020-2025” Research Report categorizes the global Cyclodextrin market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth rate, opportunities and trends,…
